Following the ESRF-EBS Upgrade, industrial activity resumed on the structural biology beamlines day one after the restart. With the huge growth of fragment-based drug discovery, it is clear that ligand-binding studies now represent the core of our services and support for pharma and biotech. Our fully automated MASSIF-1 MX beamline is our obvious winner for fragment screening, but when it comes to other types of ligand-binding studies, what about our other automated and tunable MX beamlines, our BioSAXS beamline BM29 or our microfocused MX beamline ID23-2?
In this webinar you will discover the different types of results that you can obtain from our structural biology beamlines for your ligand-binding studies.
Read more and register here
